1. Antiviral activity of ciclesonide acetal derivatives blocking SARS-CoV-2 RNA replication
- Author
-
Genichiro Tsuji, Shogo Nakajima, Koichi Watashi, Shiho Torii, Rigel Suzuki, Takasuke Fukuhara, Nobumichi Ohoka, Takao Inoue, and Yosuke Demizu
- Subjects
SARS-CoV2 ,Antiviral activity ,Ciclesonide ,Therapeutics. Pharmacology ,RM1-950 - Abstract
Ciclesonide (Cic) is approved as an inhalant for asthma and was clinically tested as a candidate therapy for coronavirus disease 2019 (COVID-19). Its active metabolite Cic2 was recently reported to suppress genomic RNA replication of severe acute respiratory syndrome coronavirus 2. In this study, we designed and synthesized a set of ciclesonide-acetal (Cic-acetal) derivatives. Among designated compounds, some Cic-acetal derivatives with a linear alkyl chain exhibited strong viral copy-number reduction activities compared with Cic2. These compounds might serve as lead compounds for developing novel anti-COVID-19 agents.
- Published
- 2022
- Full Text
- View/download PDF